A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer

Berns, Katrien, Horlings, Hugo M., Hennessy, Bryan T., Madiredjo, Mandy, Hijmans, E. Marielle, Beelen, Karin, Linn, Sabine C., Gonzalez-Angulo, Ana Maria, Stemke-Hale, Katherine, Hauptmann, Michael, Beijersbergen, Roderick L., Mills, Gordon B., van de Vijver, Marc J., Bernards, René·2007·Cancer Cell
DOI 10.1016/j.ccr.2007.08.030

Cited by (1,001)

Items 901–1,000 of 1,001

  1. Understanding the role of TNFR2 signaling in the tumor microenvironment of breast cancer
    Ali Mussa, Nor Hayati Ismail, Mahasin Hamid, Mohammad A. I. Al-Hatamleh, Anthony J. Bragoli, Khalid Hajissa, Noor Fatmawati Mokhtar, Rohimah Mohamud, Vuk Uskoković, Rosline Hassan · 2024 · Journal of Experimental & Clinical Cancer Research
  2. From genomic landscapes to personalized cancer management—is there a roadmap?
    Charles Swanton, Carlos Caldas · 2010 · Annals of the New York Academy of Sciences
  3. A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments
    Attila A. Seyhan, Usha Varadarajan, Sung E. Choe, Yan Liu, John McGraw, Matthew William Woods, Stuart Murray, Amy Eckert, Wei Liu, TERENCE EDWARD RYAN · 2011 · Molecular BioSystems
  4. HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285
    Shinji Takagi, Hiroshi Banno, Akira Hayashi, Toshiya Tamura, Tomoyasu Ishikawa, Yoshikazu Ohta · 2014 · Oncoscience
  5. Chemotherapeutics-resistance “arms” race: An update on mechanisms involved in resistance limiting EGFR inhibitors in lung cancer
    Pankaj Kumar Singh, Om Silakari · 2017 · Life Sciences
  6. Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”
    Niamh M. Keegan, Simon J. Furney, Janice Maria Walshe, Giuseppe Gullo, Megan Kennedy, Diarmuid Smith, John McCaffrey, Catherine Margaret Kelly, Keith Egan, Jennifer Kerr et al. · 2021 · Cancers
  7. The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review
    Shafighe Asgari-Karchekani, Armin Aryannejad, Seied Asadollah Mousavi, Shirin Shahsavarhaghighi, Seyed Mohammad Tavangar · 2022 · Medical Oncology
  8. The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer
    Maria Letizia Cataldo, Pietro De Placido, Daniela Esposito, Luigi Formisano, Grazia Arpino, Mario Giuliano, Roberto Bianco, Carmine De Angelis, Bianca Maria Veneziani · 2023 · Frontiers in Oncology
  9. Dissociation of Epidermal Growth Factor Receptor and ErbB2 Heterodimers in the Presence of Somatostatin Receptor 5 Modulate Signaling Pathways
    Geetanjali Kharmate, Padmesh S. Rajput, Heather L. Watt, R.K. Somvanshi, Nicole Chaudhari, Xiaofan Qiu, Ujendra Kumar · 2010 · Endocrinology
  10. Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment
    Pau Castel, Eneda Toska, Zachary Stephan Zumsteg, F. Javier Carmona, Moshe Elkabets, Ana Bosch, Maurizio Scaltriti · 2014 · Molecular & Cellular Oncology
  11. PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer
    Parvin F. Peddi, Sara Alsterlind Hurvitz · 2014 · Journal of Neuro-Oncology
  12. Genome-based and transcriptome-based molecular classification of breast cancer
    Ivan Bièche, Rosette Lidereau · 2010 · Current Opinion in Oncology
  13. Targeting Cancer Stem Cells with Defined Compounds and Drugs
    Cord Naujokat, Stefan Laufer · 2013 · Journal of cancer research updates
  14. Mycophenolic acid potentiates HER2-overexpressing SKBR3 breast cancer cell line to induce apoptosis: involvement of AKT/FOXO1 and JAK2/STAT3 pathways
    Safiyeh Aghazadeh, Razieh Yazdanparast · 2016 · APOPTOSIS
  15. Inhibition of PI3K signaling pathway enhances the chemosensitivity of APL cells to ATO: Proposing novel therapeutic potential for BKM120
    Davood Bashash, Mahda Delshad, Niknam Riyahi, Ava Safaroghli‐Azar, Atieh Pourbagheri‐Sigaroodi, Majid Momeny · 2018 · European Journal of Pharmacology
  16. Targeted next generation sequencing identifies somatic mutations in a cohort of Egyptian breast cancer patients
    Auhood Abdel-Monem Nassar, Mohamed Ibrahim Abouelhoda, Osman Mohamed Mansour, Samah Aly Loutfy, Mohamed Mahmoud Hafez, Mohammed Mohammed Mohammed Gomaa, Abeer Ahmed Bahnassy, Amira Salah El-Din Youssef, Mai M. Lotfy, Hoda M Ismail et al. · 2020 · Journal of Advanced Research
  17. RNA interference screening demystified
    Christopher J. Lord, Sarah A. Martin, Alan Ashworth · 2009 · Journal of Clinical Pathology
  18. Interleukin 7 receptor alpha Thr244Ile genetic polymorphism is associated with susceptibility and prognostic markers in breast cancer subgroups
    Glauco Akelinghton Freire Vitiello, Roberta Losi Guembarovski, Marla Karine Amarante, Jesus Roberto Ceribelli, Elaine Cristina Baraldi Carmelo, Maria Angélica Ehara Watanabe · 2017 · Cytokine
  19. Clinical Development of Phosphatidylinositol-3 Kinase Pathway Inhibitors
    Carlos L. Arteaga · 2010 · Current topics in microbiology and immunology
  20. A Lentivirus-Mediated Genetic Screen Identifies Dihydrofolate Reductase (DHFR) as a Modulator of β-Catenin/GSK3 Signaling
    Richard A. Klinghoffer, Jason P. Frazier, James E. Annis, Jason D. Berndt, Brian S. Roberts, William T. Arthur, Raul Lacson, Xiaohua Douglas Zhang, Marc Ferrer, Randall T. Moon et al. · 2009 · PLoS ONE
  21. Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines
    Julia Kneißl, Anja Hartmann, Nicole Pfarr, Franziska Erlmeier, Thomas Lorber, Simone Keller, Gwen Zwingenberger, Wilko Weichert, Birgit Luber · 2016 · Journal of Cancer Research and Clinical Oncology
  22. Single-Circulating Tumor Cell Whole Genome Amplification to Unravel Cancer Heterogeneity and Actionable Biomarkers
    Tanzila Khan, Therese M. Becker, Joseph William Po, Wei Ming Chua, Yafeng Ma · 2022 · International Journal of Molecular Sciences
  23. Detailed curriculum vitae of HER2-targeted therapy
    Xiaonan Zhang, Ya Gao, Xi-Ya Zhang, Ning-Jie Guo, Wenqing Hou, Shu-Wu Wang, Yi‐Chao Zheng, Ning Wang, Hong‐Min Liu, Bo Wang · 2023 · Pharmacology & Therapeutics
  24. Modulation of cell sensitivity to antitumor agents by targeting survival pathways
    Paola Perego, Giacomo Cossa, Valentina Zuco, Franco Zunino · 2010 · Biochemical Pharmacology
  25. Resistance to HER2-targeted therapies: a potential role for FOXM1
    Bridgette F. Peake, Rita Nahta · 2014 · Breast Cancer Management
  26. Correlation of Breast Cancer Axillary Lymph Node Metastases With Stem Cell Mutations
    Cory Donovan, Rodney F. Pommier, Robynn V. Schillace, Steven O’Neill, Patrick Muller, Jennifer L. Alabran, Juliana E. Hansen, Jennifer A. Murphy, Arpana M. Naik, John T. Vetto et al. · 2013 · JAMA Surgery
  27. Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic
    Alessandra Fabi, Marcella Mottolese, Oreste Segatto · 2014 · Journal of Molecular Medicine
  28. Src Mutation Induces Acquired Lapatinib Resistance in ERBB2-Amplified Human Gastroesophageal Adenocarcinoma Models
    Yong Sang Hong, Jihun Kim, Eirini Pectasides, Cameron Fox, Seungwoo Hong, Qiuping Ma, Gabrielle S. Wong, Shouyong Peng, Matthew D. Stachler, Aaron R. Thorner et al. · 2014 · PLoS ONE
  29. In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib
    Ashok K. Chakraborty, Cynthia A. Zerillo, Michael P. DiGiovanna · 2015 · Breast Cancer Research and Treatment
  30. Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications
    Sònia Pernas · 2014 · Therapeutic Advances in Medical Oncology
  31. Development of a peptide by phage display for SPECT imaging of resistance-susceptible breast cancer.
    Benjamin M. Larimer, Susan L. Deutscher · 2014 · Europe PMC (PubMed Central)
  32. Monitoring Trastuzumab Resistance and Cardiotoxicity
    Milos Dokmanovic, Wen Jin Wu · 2015 · Advances in clinical chemistry
  33. FOXOs Maintaining the Equilibrium for Better or for Worse
    Sabina van Doeselaar, Boudewijn M.T. Burgering · 2018 · Current topics in developmental biology/Current Topics in Developmental Biology
  34. Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model
    Sharon Glaysher, Louise M Bolton, Penny Johnson, Christopher J. Torrance, Ian A. Cree · 2014 · BMC Research Notes
  35. Everolimus in hormone receptor–positive advanced breast cancer: Targeting receptor-based mechanisms of resistance
    Mikhail I. Shtivelband · 2013 · The Breast
  36. MIDAS: Mining differentially activated subpaths of KEGG pathways from multi-class RNA-seq data
    Sangseon Lee, Youngjun Park, Sun Kim · 2017 · Methods
  37. Sensitivity to TOP2 Targeting Chemotherapeutics Is Regulated by Oct1 and FILIP1L
    Huarui Lu, Timothy Curtis Hallstrom · 2012 · PLoS ONE
  38. Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer
    Zhifei Li, Huan Zhao, Huihui Hu, Hai-Li Shang, Yongjing Ren, Wenhui Qiu, Hao Su, Huifang Lyu, Xiaobing Chen · 2024 · Chinese Journal of Cancer Research
  39. Mechanisms of resistance to antibody–drug conjugates in cancers
    Yuya Murase, Shigeki Nanjo, Tsukasa Ueda, Liu Yifeng, Shunichi Nomura, Sachiko Arai, Nanao Terada, Hayato Koba, Yuichi Tambo, Seiji Yano · 2025 · Respiratory Investigation
  40. Pharmacogenomic Contribution to Drug Response
    Roshawn Watson, Howard L. McLeod · 2011 · The Cancer Journal
  41. Evaluation of the Tocilizumab therapy in human cancers: Latest evidence and clinical potential
    Kosar Ghasemi, Kosar Ghasemi · 2022 · Journal of Clinical Pharmacy and Therapeutics
  42. Molecular correlates of invasion pattern in HPV‐associated endocervical adenocarcinoma: emergence of two distinct risk‐stratified tiers
    Aarti E. Sharma, Anjelica Hodgson, Brooke E. Howitt, Ekaterina Olkhov‐Mitsel, Bojana Djordevic, Kay J. Park, Marisa R. Nucci, Carlos Parra‐Herran · 2023 · Histopathology
  43. Circulating tumor cells and circulating tumor DNA in breast cancer diagnosis and monitoring
    Effat Alemzadeh, Leila Allahqoli, Hamideh Dehghan, Afrooz Mazidimoradi, Alireza Ghasempour, Hamid Salehiniya · 2023 · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
  44. Long road towards effective HER3 targeting in breast cancer
    Francesca Papa, Thomas Grinda, Elie Rassy, Rasha Cheikh-Hussin, Joana Mourato Ribeiro, Lorenzo Antonuzzo, Barbara Pistilli · 2024 · Cancer Treatment Reviews
  45. Integration of cancer genomics with treatment selection
    Thomas Julian Ow, Vlad Constantin Sandulache, Heath Devin Skinner, Jeffrey N. Myers · 2013 · Cancer
  46. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells
    Chi Zhang, Xuening Duan, Ling Xu, Jingming Ye, Jianxin Zhao, Yinhua Liu · 2012 · Breast Cancer Research and Treatment
  47. PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer
    Daphne Gschwantler‐Kaulich, Yen Y. Tan, Eva‐Maria Fuchs, Gernot Hudelist, Wolfgang J. Köstler, Reiner Angelika, Carmen Leser, Mohamed Mamdouh Salama, Johannes Attems, Christine Deutschmann et al. · 2017 · PLoS ONE
  48. The role of neratinib in HER2-driven breast cancer
    Mathew Amprayil Cherian, Cynthia X. Ma · 2017 · Future Oncology
  49. Pathways Linked to Cancer Chemoresistance and Their Targeting by Nutraceuticals
    Alok Chandra Bharti, Kanchan Vishnoi, Sukh Mahendra Singh, Bharat Bhushan Aggarwal · 2017 · Elsevier eBooks
  50. Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives
    Enrique Soto‐Pérez‐de‐Celis, Kah Poh Loh, Capucine Baldini, Nicolò Matteo Luca Battisti, Yanin Chávarri-Guerra, Nienke A. de Glas, Tina Hsu, Arti Hurria · 2018 · Expert Opinion on Investigational Drugs
  51. Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report
    Le‐Tian Huang, Jie‐Tao Ma, Shuling Zhang, Xiaohan Li, Li Sun, Wei Jing, Jianzhu Zhao, Yan-Ru Wang, Cheng‐Bo Han · 2019 · Frontiers in Oncology
  52. PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma
    Daiju Yokoyama, Shigeo Hisamori, Yasunori Deguchi, Tatsuto Nishigori, Hiroshi Okabe, Seiichiro Kanaya, Dai Manaka, Yoshio Kadokawa, Hiroaki Hata, Sachiko Minamiguchi et al. · 2021 · Scientific Reports
  53. Apoptosis induction in human lung and colon cancer cells via impeding VEGF signaling pathways
    Maryam Farzaneh Behelgardi, Zahra Gholami Shahvir, Seyed Mohsen Asghari · 2022 · Molecular Biology Reports
  54. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses
    Yufeng Xie, Y Chen, Khawaja Ashfaque Ahmed, W Li, Shahid Ahmed, Amer Sami, Rajni Chibbar, Xiaoying Tang, Min Tao, Jianqing Xu et al. · 2013 · Cancer Gene Therapy
  55. Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers
    Ramón González Manzano, E. Martinez-Navarro, Jerónimo Forteza, Antonio Brugarolas · 2014 · International Journal of Oncology
  56. The Dark Side of the Moon: The PI3K/PTEN/AKT Pathway in Colorectal Carcinoma
    Nicola Silvestris, Stefania Tommasi, Daniela Petriella, Daniele Santini, Ettore Fistola, Antonio Dello Russo, Gianmauro Numico, Giuseppe Tonini, Evaristo Maiello, Giuseppe Colucci · 2009 · Oncology
  57. “The Infinite Maze” of breast cancer, signaling pathways and radioresistance
    Orit Kaidar‐Person, Christine S. Lai, Abraham Kuten, Yazid Belkacémi · 2013 · The Breast
  58. Adipocyte-conditioned medium induces resistance of breast cancer cells to lapatinib
    Aline Geneste, Minh Ngoc Duong, L. Molina, Louise Conilh, Sabine Beaumel, Aurore Cleret, Kamel Chettab, Maëlle Lachat, Lars Petter Jordheim, Eva‐Laure Matera et al. · 2020 · BMC Pharmacology and Toxicology
  59. Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases
    Daniel R Owen, Hui‐Li Wong, Melika Bonakdar, Martin R. Jones, Christopher S. Hughes, Gregg B. Morin, Steven J.M. Jones, Daniel John Renouf, Howard John Lim, Janessa J. Laskin et al. · 2018 · Molecular Case Studies
  60. A signaling molecule from intratumor bacteria promotes trastuzumab resistance in breast cancer cells
    Gege Qin, Xiying Shao, Xiaolong Liu, Jiachao Xu, Xiaojia Wang, Wenxi Wang, Lu Gao, Yuxin Liang, Lina Xie, Dan Su et al. · 2025 · Proceedings of the National Academy of Sciences
  61. YAP increases response to Trastuzumab in HER2-positive Breast Cancer by enhancing P73-induced apoptosis
    Lanqing Cao, Min Yao, Hironobu Sasano, Ping-Li Sun, Hongwen Gao · 2020 · Journal of Cancer
  62. Discriminating Origin Tissues of Tumor Cell Lines by Methylation Signatures and Dys-Methylated Rules
    Shiqi Zhang, Tao Zeng, Bin Hu, Yuhang Zhang, Kaiyan Feng, Lei Chen, Zhibin Niu, Jianhao Li, Tao Huang, Yu‐Dong Cai · 2020 · Frontiers in Bioengineering and Biotechnology
  63. PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
    Liliana Ascione, Paola Zagami, Eleonora Nicolò, Edoardo Crimini, Giuseppe Curigliano, Carmen Criscitiello · 2022 · Journal of Personalized Medicine
  64. Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer
    Toru Mukohara · 2011 · Chemotherapy Research and Practice
  65. Exploration of Synthetic Lethal Interactions as Cancer Drug Targets
    Hendrik J. Kuiken, Roderick L. Beijersbergen · 2010 · Future Oncology
  66. Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
    Laura García‐Estévez, Ana Suárez‐Gauthier, Elena García, Cristina Martínez Miró, Isabel Calvo, María Fernández-Abad, Mercedes Herrero, Manuel Marcos, Cristina Márquez, Fernando López Ríos et al. · 2014 · Breast Cancer Research
  67. Involvement of microRNAs in HER2 signaling and trastuzumab treatment
    Ling Mao, Aijun Sun, Jian-zhong Wu, Jinhai Tang · 2016 · Tumor Biology
  68. Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease
    Ashok K. Chakraborty, Christos Hatzis, Michael P. DiGiovanna · 2017 · Breast Cancer Research and Treatment
  69. Antitumor activity of NAX060: A novel semisynthetic berberine derivative in breast cancer cells
    Elisa Pierpaoli, Gaetano Fiorillo, Paolo Lombardi, Carmela Salvatore, Cristina Geroni, Francesco Piacenza, Mauro Provinciali · 2018 · BioFactors
  70. Clinical application of circulating tumor DNA in breast cancer
    Jeffrey Chun Hin Chan, James Chung Hang Chow, Connie Hoi Man Ho, Therese Yue Man Tsui, William Chi Shing Cho · 2021 · Journal of Cancer Research and Clinical Oncology
  71. New developments in the treatment of HER2-positive breast cancer
    Rita Nahta · 2012 · Breast Cancer Targets and Therapy
  72. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models
    Guodong Shen, Hui Huang, Anli Zhang, Ting Zhao, Siyi Hu, Liansheng Cheng, Jing L. Liu, Weihua Xiao, Bin Ling, Qiang Wu et al. · 2010 · Cancer Immunology Immunotherapy
  73. From man to mouse and back again: advances in defining tumor AKTivities in vivo
    David F. Restuccia, Brian A. Hemmings · 2010 · Disease Models & Mechanisms
  74. Combating trastuzumab resistance by targeting thioredoxin-1/PTEN interaction
    Akram Sadeghirizi, Razieh Yazdanparast, Safiyeh Aghazadeh · 2015 · Tumor Biology
  75. New Insights Into Cellular Stress Responses to Environmental Metal Toxicants
    Hae‐Ryung Park, Raymond S. Oh, P. Wagner, Ronald Allan M. Panganiban, Quan Lu · 2016 · International review of cytology
  76. PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis
    Youjeong Seo, Yeon Hee Park, Jin Seok Ahn, Young‐Hyuck Im, Seok Jin Nam, Soo Youn Cho, Eun Yoon Cho · 2018 · Journal of Breast Cancer
  77. Molecular alterations and poziotinib efficacy, a pan‐HER inhibitor, in human epidermal growth factor receptor 2 (HER2)‐positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2‐positive breast cancer patients
    Ji‐Yeon Kim, Eunjin Lee, Kyunghee Park, Hae Hyun Jung, Woong‐Yang Park, Kyung‐Hun Lee, Joohyuk Sohn, Keun Seok Lee, Kyung Hae Jung, Jee Hyun Kim et al. · 2019 · International Journal of Cancer
  78. Rapid, Cost-Effective Peptide/Nucleic Acid-Based Platform for Therapeutic Antibody Monitoring in Clinical Samples
    Marco Mocenigo, Alessandro Porchetta, Marianna Rossetti, Erik Brass, Lucia Tonini, Luca Puzzi, Elda Tagliabue, Tiziana Triulzi, Bruna Marini, Francesco Ricci et al. · 2020 · ACS Sensors
  79. Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions
    Gonzálo Recondo · 2014 · World Journal of Clinical Oncology
  80. The application of gene silencing in proteomics: from laboratory to clinic
    Maura Brioschi, Cristina Banfi · 2018 · Expert Review of Proteomics
  81. A Novel Mechanism Underlying the Inhibitory Effects of Trastuzumab on the Growth of HER2-Positive Breast Cancer Cells
    Hamid Maadi, Zhixiang Wang · 2022 · Cells
  82. YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT/mTOR and ERK/mTOR axis
    Jiao Qiao, Mei Feng, Wenyuan Zhou, Yuan Tan, Shuo Yang, Qi Liu, Qingchen Wang, Weimin Feng, Yisheng Pan, Liyan Cui · 2024 · Gastric Cancer
  83. Evolving Management of Breast Cancer in the Era of Predictive Biomarkers and Precision Medicine
    Muhammad Zubair Afzal, Linda T. Vahdat · 2024 · Journal of Personalized Medicine
  84. Evaluation of HER2 in breast cancer: reality and expectations
    Fernanda Milanezi, Dina Leitão, Sara Alexandra Vinhas Ricardo, Isabel Augusto, Fernando Carlos Schmitt · 2009 · Expert Opinion on Medical Diagnostics
  85. E‐cadherin expression on human carcinoma cell affects trastuzumab‐mediated antibody‐dependent cellular cytotoxicity through killer cell lectin‐like receptor G1 on natural killer cells
    Chisako Yamauchi, Satoshi Fujii, Taichi Kimura, Takeshi Kuwata, Noriaki Wada, Hirofumi Mukai, Naoki Matsumoto, Masashi Fukayama, Atsushi Ochiai · 2010 · International Journal of Cancer
  86. BCL-2 family genetic profiling reveals microenvironment-specific determinants of chemotherapeutic response
    Luke A. Gilbert, Corbin E. Meacham, Hai Jiang, Michael T. Hemann, Justin R. Pritchard, Shingleton, Jennifer R., Douglas A. Lauffenburger · 2011 · DSpace@MIT (Massachusetts Institute of Technology)
  87. Predictive and Prognostic Significance of p27, Akt, PTEN and PI3K Expression in HER2-Positive Metastatic Breast Cancer
    Kerem Okutur, Nuray Başsülü, Levent Dalar, Kübra Aydın, Mustafa Bozkurt, Kezban Nur Pilancı, Gülen Doğusoy, C. Tecimer, Nil Molinas Mandel, Gökhan Demir · 2015 · Asian Pacific Journal of Cancer Prevention
  88. Current views on inducing synthetic lethal RNAi responses in the treatment of cancer
    Apollo D. Kacsinta, Steven F. Dowdy · 2015 · Expert Opinion on Biological Therapy
  89. An anti-ErbB2 fully human antibody circumvents trastuzumab resistance
    Qiong Lu, Lingfei Wang, Yajun Zhang, Xiaojie Yu, Chao Wang, Huajing Wang, Yang� Yang, Xiaodan Chong, Tian Xia, Yanchun Meng et al. · 2016 · Oncotarget
  90. Novel Targeted Agents and Immunotherapy in Breast Cancer
    Ingrid A. Mayer, Rebecca Alexandra Dent, Tira J. Tan, Peter Stephen Savas, Sherene Loi · 2017 · American Society of Clinical Oncology Educational Book
  91. Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing
    Sangjoon Choi, Jinah Chu, Binnari Kim, Sang Yun Ha, Seung Tae Kim, Jeeyun Lee, Won Ki Kang, Heewon Han, Insuk Sohn, Kyoung‐Mee Kim · 2019 · Journal of Molecular Diagnostics
  92. Targeting of β-Catenin Reverses Radioresistance of Cervical Cancer with the PIK3CA -E545K Mutation
    Wei Jiang, Yutuan Wu, Tiancong He, Hanting Zhu, Guihao Ke, Libing Xiang, Huijuan Yang · 2019 · Molecular Cancer Therapeutics
  93. Cyclin E overexpression confers resistance to trastuzumab through noncanonical phosphorylation of SMAD3 in HER2+ breast cancer
    Joseph T. Decker, Pridvi Kandagatla, Lei Wan, Regan Bernstein, Jeffrey A. Ma, Lonnie D. Shea, Jacqueline Sara Jeruss · 2020 · Cancer Biology & Therapy
  94. The Biophysics of Cancer: Emerging Insights from Micro‐ and Nanoscale Tools
    Peter E. Beshay, Marcos G. Cortes-Medina, Miles M. Menyhert, Jonathan W. Song · 2021 · Advanced NanoBiomed Research
  95. Dual-specificity phosphatase 8 (DUSP8) induces drug resistance in breast cancer by regulating MAPK pathways
    Hanchao Zhang, Meng Wang, Di Chen, Chengyu Luo · 2022 · Journal of Investigative Medicine
  96. Novel Targeted Agents for the Treatment of Advanced Breast Cancer
    Martha Vega, Enrique A. Diaz-Canton, Ricardo H. Álvarez · 2012 · Future Medicinal Chemistry
  97. n-3 polyunsaturated fatty acids and HER2-positive breast cancer: Interest of the fat-1 transgenic mouse model over conventional dietary supplementation
    Zuquan Zou, Célia Bidu, Sandrine Bellenger, Michel Narce, Jérôme Bellenger · 2013 · Biochimie
  98. HER2-positive gastric cancer with paraaortic nodal metastasis successfully resected after chemotherapy with trastuzumab: a case report.
    Naoki Ikari, Go Nakajima, Kiyoaki Taniguchi, Tsuyoshi Sasagawa, Kosuke Narumiya, Takuji Yamada, Kenji Kudo, Yoichi Kitamura, Kazuhiko Hayashi, Toshio Nishikawa et al. · 2014 · PubMed
  99. Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors
    Komal L. Jhaveri, Sarat Chandarlapaty, Neil M. Iyengar, Patrick Glyn Morris, Adriana Dionigi Corben, Sujata N Patil, Muzaffar M. Akram, Russell Towers, Rita A. Sakr, Tari A. King et al. · 2015 · Clinical Breast Cancer
  100. Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells
    Sonja Thaler, Martina Schmidt, Sven Roßwag, Gitta Thiede, Arno Schad, Jonathan Paul Sleeman · 2017 · Oncotarget